Sharing of Revenues. 6.1 Subject to the terms of any third-party relationship established in accordance with section 4 hereto, all Net Proceeds related to the Commercialization, licensing or other form of exploitation of the Project Intellectual Property shall be allocated between the University and the Inventors in accordance with Article 27.18(a) of the CUFA Collective Agreement as follows: Fifty percent (50%) to the Inventors in the proportions identified under Section 3 of DOI 20XX-XX; AND Fifty percent (50%) to the University.
6.2 In the event the Commercialization of the Project Intellectual Property leads to the establishment of a legal person (body corporate) or other entity, whether incorporated or otherwise in any jurisdiction whether Canadian or foreign, (the “Company”) for the exploitation or licensing of the Project Intellectual Property, the University, the Inventor and any third party shall negotiate their respective participation in the Company. Such negotiation shall be subject to the terms of this Agreement, and shall acknowledge this Agreement by signing it. Further, the amount of any development funds made available and the relevant mechanism through which it is repaid, the participation of any other parties, together with any other matter which the parties consider relevant, shall be subject to the terms of this Agreement.
6.3 All Net Proceeds shall be distributed in accordance with Articles 27.18 (a) and 27.19 of the CUFA Collective Agreement.
Sharing of Revenues. 5.1 Subject to the terms of any third-party relationship established in accordance with section 4 hereto, where the University has at any time handled the protection and Commercialization activities relating to the Project Intellectual Property, all Net Proceeds related to the Commercialization of the Project Intellectual Property, whether the Project Intellectual Property be a Qualifying or Independent Project Intellectual Property, shall be allocated between the University and the Inventors in accordance with Article 27.18 (a), Article 27.18 (b), or Article 27.18 (c) as the case may be, of the CUFA Collective Agreement.
5.2 In the event the Commercialization of the Project Intellectual Property leads to the establishment of a legal person (body corporate) or other entity, whether incorporated or otherwise in any jurisdiction whether Canadian or foreign, (the “Company”) for the exploitation or licensing of the Project Intellectual Property, the University, the Inventor and any third party shall negotiate their respective participation in the Company.
5.3 All reporting and distribution of Net Proceeds as required under this Agreement and CUFA Article 27 shall be done in accordance with Article 27.19 of the CUFA Collective Agreement.
Sharing of Revenues. 6.1 Subject to the terms of any third-party relationship established in accordance with section 4 hereto, all Net Proceeds related to the Commercialization, licensing or other form of exploitation of the Project Intellectual Property shall be allocated between the University and the Inventors in accordance with Article 27.18(a), Article 27.18 (b), or Article 27.18 (c), as the case may be, of the CUFA Collective Agreement.
6.2 In the event the Commercialization of the Project Intellectual Property leads to the establishment of a legal person (body corporate) or other entity, whether incorporated or otherwise in any jurisdiction whether Canadian or foreign, (the “Company”) for the exploitation or licensing of the Project Intellectual Property, the University, the Inventor and any third party shall negotiate their respective participation in the Company.
6.3 All reporting and distribution of Net Proceeds as required under this Agreement and CUFA Article 27 shall be done in accordance with Article 27.19 of the CUFA Collective Agreement.
Sharing of Revenues. 5.1 Subject to the terms of any third-party relationship established in accordance with section 4 hereto, where the University has at any time handled the protection and Commercialization activities relating to the Project Intellectual Property, all Net Proceeds related to the Commercialization of the Project Intellectual Property, whether the Project Intellectual Property be a Qualifying or Independent Project Intellectual Property, shall be allocated between the University and the Inventors in accordance with Article 27.18 (a) of the CUFA Collective Agreement as follows: Fifty percent (50%) to the Inventors in the proportions identified under Section 3 of DOI 20XX-XX ; AND Fifty percent (50%) to the University
5.2 In the event the Commercialization of the Project Intellectual Property leads to the establishment of a legal person (body corporate) or other entity, whether incorporated or otherwise in any jurisdiction whether Canadian or foreign, (the “Company”) for the exploitation or licensing of the Project Intellectual Property, the University, the Inventor and any third party shall negotiate their respective participation in the Company. Such negotiation shall be subject to the terms of this Agreement, and shall acknowledge this Agreement by signing it. Further, the amount of any development funds made available and the relevant mechanism through which it is repaid, the participation of any other parties, together with any other matter which the parties consider relevant, shall be subject to the terms of this Agreement.
5.3 All Net Proceeds shall be distributed in accordance with Articles 27.18 (a) and 27.19 of the CUFA Collective Agreement.
Sharing of Revenues. [**] CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT. THROUGHOUT THIS EXHIBIT CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THE PUBLIC FILING AND HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. The Parties shall share Service Revenues (as defined below) as follows: [**] StarMedia [**] Critical Path The Parties shall share in the Net Advertising Revenues (as defined below) as follows: [**] StarMedia [**] Critical Path
Sharing of Revenues. 5.1 Subject to the terms of any third-party relationship established in accordance with section 4 hereto, where the University has at any time handled the protection and Commercialization activities relating to the Project Intellectual Property, all Net Proceeds related to the Commercialization of the Project Intellectual Property, whether the Project Intellectual Property be a Qualifying or Independent Project Intellectual Property, shall be allocated between the University and the Inventors in accordance with Article 27.18 (a) of the CUFA Collective Agreement as follows: 50% to the Inventors in the proportions identified under Section 3 of DOI 20XX- XX ; AND 50% to the University
5.2 In the event the Commercialization of the Project Intellectual Property leads to the establishment of a legal person (body corporate) or other entity, whether incorporated or otherwise in any jurisdiction whether Canadian or foreign, (the “Company”) for the exploitation or licensing of the Project Intellectual Property, the University, the Inventor and any third party shall negotiate their respective participation in the Company. Such negotiation shall be subject to the terms of this Agreement, and shall acknowledge this Agreement by signing it. Further, the amount of any development funds made available and the relevant mechanism through which it is repaid, the participation of any other parties, together with any other matter which the parties consider relevant, shall be subject to the terms of this Agreement.
5.3 All Net Proceeds shall be distributed in accordance with Articles 27.18 (a) and 27.19 of the CUFA Collective Agreement.
Sharing of Revenues. 2.1 ACCESSORY REVENUE arising from the exploitation of RELATED ACTIVITY shall be shared by the CONCESSIONAIRE in favor of the GRANTING AUTHORITY in the proportion of:
Sharing of Revenues. Cogenco and DMI will share equally Profits on Sales made by either one of them of Products and will share equally all payments received from third-party licensees and sublicensees, including licensing fees, sublicensing fees, milestone payments and royalties. The parties intend that such CODA will be structured in order to minimize any tax consequences arising from the proposed Phase II Merger described below.
Sharing of Revenues. Level 1 From the first "*Filed Separately with the Commission*" of annual ------- sales revenues received by Signet from sales of Cell Line Products, Signet shall retain "*Filed Separately with the Commission*" of annual sales revenues, plus reasonable production costs consistent with Senetek's agreement with Covance Research Products, Inc., plus reasonable charges for QA/QC compliance not to exceed "*Filed Separately with the Commission*" annually, plus sales and distribution taxes [including, but not limited to, federal manufacturer's and retailer's excise, state and local sales and use taxes and personal property taxes), value-added taxes, public charges, tariffs, import duties, quarantine charges or license fees however designated, levied or based on such prices (hereinafter referred to as "Taxes")]. The remainder of the sales revenues shall be remitted to Senetek. Senetek shall be responsible for all fees due to RFMH in accordance with the Basic Agreement/ License.
Level 2 From annual sales revenues in excess of "*Filed Separately with the ------- Commission*" received by Signet from sales of Cell Line Products, Signet shall pay "*Filed Separately with the Commission*"of annual sales revenues in excess of "*Filed Separately with the Commission*" and all fees due RFMH in accordance with the Basic Agreement/License. Signet is responsible for costs and expenses incurred in connection with the sale of Cell Line Products. Level 3 "New Cell Line Products" are described as products which are not ------- listed on Exhibit A, including derivatives of Cell Line Products and additional products obtained from RFMH for sale under this agreement. From annual sales revenues received by Signet from sales of new Cell Line Products, Signet shall pay to Senetek "*Filed Separately with the Commission*" of annual sales revenues. Signet is responsible for all costs and expenses incurred in connection with the sale of New Cell Line Products. Signet shall be responsible for all fees due to RFMH in accordance with the Basic Agreement/License. If at any time during the first three (3) years of this Agreement, a derivative product significantly impacts sales of Level 1 Cell Line Products, Senetek and Signet may re-negotiate a revenue-sharing agreement for those derivative products.
Sharing of Revenues. (a) In the event Section 4.2 is applicable, in lieu of any payment set forth in Section 4.1, TG and CFFT shall [*], whether in the form of [*] (collectively, “Licensing Income”) paid to TG for the grant of any license or the transfer of TG’s rights to develop and market the Product in the U.S., [*] after the repayment of:
(1) first, [*] of the Contribution plus an additional [*] of such amount to CFFT (the “CFFT Repayment Amount”); and * Confidential treatment requested.
(2) following repayment of the CFFT Repayment Amount, the [*] to the date of such transfer to TG (the “TG Repayment Amount”). A final accounting of the TG Repayment Amount shall be provided to CFFT promptly, but in no case later than [*], after the execution of the final agreement for such transfer.
(b) Payments under this Section 4.4 from CFFT to TG of CFFT’s share of Licensing Income shall be made within [*] of CFFT’s receipt of any Licensing Income and shall be made first to CFFT until the CFFT Repayment Amount has been [*] and then to TG until the TG Repayment Amount has been [*], and thereafter shall be split, on [*].
